SOBRERO, Alberto
SOBRERO, Alberto
DIP. RICERCHE MEDICHE E MORFOLOGICHE - DIRM (attivo dal 01/01/1900 al 22/09/2011)
5-Fluorouracil may have different mechanisms of action depending on the dose schedule: clinical implications
1994-01-01 C., Aschele; Sobrero, Alberto; A., Guglielmi; A., Mori; L., Tixi; E., Bolli; R., Rosso; Jr, Bertino
5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer
2001-01-01 Sobrero, Alberto; Guglielmi, A; Cirillo, M; Recaldin, E; Frassineti, Gl; Aschele, C; Ravaioli, A; Estore, P; Caroti, C; Gallo, L; Pessi, Ma; Cortesi, E; Turci, D; Rossi, F; Labianca, R.
A randomized trial of 5-fluorouracil alone vs 5-FU and high dose leucovorin in untreated advanced colorectal cancer patients
1988-01-01 Nobile, Mt; Canobbio, L; Sobrero, Alberto; Galligioni, E; Vidili, Mg; Rubagotti, A; Sertoli, Mr; Rosso, R.
Activity of 4'Epi-doxorubicin on normal haemopoietic precursor cells in mice
1982-01-01 Sobrero, Alberto; Muzzulini, C; D'Amore, F; Ghio, R; Pannacciulli, I.
Activity of continuous infusion 5-Fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-Fluorouracil
1993-01-01 A., Mori; S., Bertoglio; A., Guglielmi; C., Aschele; E., Bolli; L., Tixi; R., Rosso; Sobrero, Alberto
Adjuvant chemotherapy in the treatment of colon cancer: randomized multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC)
2003-01-01 Di Costanzo, F; Sobrero, Alberto; Gasperoni, S; Dogliotti, L; Frassineti, L; Falcone, A; Lionetto, R; Bruzzi, P; Luppi, G; Gallo, L; Conte, P; Comandone, A; Turci, D; Marzola, M; Folco, U; Pfanner, E; Mestriner, M; Boni, C; Galli, C; Tonato, M; Rosso, R.
Adjuvant sequential methotrexate --> 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer
2005-01-01 Sobrero, Alberto; Frassineti, G; Falcone, A; Dogliotti, L; Rosso, R; Costanzo, Fd; Bruzzi, P; Intacc,
Adjuvant therapy for colon cancer: 12 months, 9 months, 6 months ... why not 3 months?
2005-01-01 Sobrero, Alberto; Sciallero, S.
Adjuvant treatment of colorectal cancer in the elderly
1995-01-01 C., Aschele; A., Guglielmi; L., Tixi; E., Bolli; A., Mori; R., Lionetto; R., Rosso; Sobrero, Alberto
Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial
2007-01-01 Cascinu, S; Labianca, R; Barone, C; Santoro, A; Carnaghi, C; Cassano, A; Beretta, Gd; Catalano, V; Bertetto, O; Barni, S; Frontini, L; Aitini, E; Rota, S; Torri, V; Floriani, I; Italian Group for the Study of Digestive Tract, Cancer; Pozzo, C; Rimassa, L; Mosconi, S; Giordani, P; Ardizzoia, A; Foa, P; Rabbi, C; Chiara, S; Gasparini, G; Nardi, M; Mansutti, M; Arnoldi, E; Piazza, E; Cortesi, E; Pucci, F; Silva, Rr; Sobrero, Alberto; Ravaioli, A.
Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients
1996-01-01 A., Guglielmi; C., Aschele; F., Grossi; L., Tixi; Sobrero, Alberto
Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy
2009-01-01 Peeters, M; Siena, S; Van Cutsem, E; Sobrero, Alberto; Hendlisz, A; Cascinu, S; Kalofonos, H; Devercelli, G; Wolf, M; Amado, Rg
Bevacizumab plus fluorouracil: the value of being part of a developing story
2005-01-01 Sobrero, Alberto; Bruzzi, P.
Biochemical determinants of antineoplastic activity of fluoropyrimidines
1989-01-01 Sobrero, Alberto; Russello, O; Aschele, C; Gamba, E; Bruzzo, C; Maioli, D; Nobile, Mt; Vidili, Mg; Nicolin, A.
Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer : economic evaluation in an Italian NHS setting
2008-01-01 Di Costanzo, F; Ravasio, R; Sobrero, Alberto; Bertetto, O; Vinante, O; Luppi, G; Labianca, R; Amadori, D; Barone, C; Carlo Merlano, M; Longo, F; Mansueto, G; Antonuzzo, L; Gasperoni, S.
Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study
2005-01-01 Twelves, Cj; Butts, Ca; Cassidy, J; Conroy, T; Braud, F; Diaz Rubio, E; Tabernero, Jm; Schoffski, P; Figer, A; Brunet, R; Grossmann, J; Sobrero, Alberto; Van Cutsem, Ej
Chemosensitivity of human tumor clonogenic cells simultaneously assayed in agar diffusion chambers and in a two-layer agar culture system
1984-01-01 Sobrero, Alberto; Marsh, Jc
Chemotherapy: which drug and when?
2010-01-01 Sobrero, Alberto; Bennicelli, E.
Clinical aspects of drug resistance
1986-01-01 Sobrero, Alberto; Bertino, Jr
Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel Liver Metastases Workshop
2009-01-01 Nordlinger, B; Van Cutsem, E; Gruenberger, T; Glimelius, B; Poston, G; Rougier, P; Sobrero, Alberto; Ychou, M; European Colorectal Metastases Treatment, Group; Sixth International, Colorectal
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| 5-Fluorouracil may have different mechanisms of action depending on the dose schedule: clinical implications | 1-gen-1994 | C., Aschele; Sobrero, Alberto; A., Guglielmi; A., Mori; L., Tixi; E., Bolli; R., Rosso; Jr, Bertino | |
| 5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer | 1-gen-2001 | Sobrero, Alberto; Guglielmi, A; Cirillo, M; Recaldin, E; Frassineti, Gl; Aschele, C; Ravaioli, A; Estore, P; Caroti, C; Gallo, L; Pessi, Ma; Cortesi, E; Turci, D; Rossi, F; Labianca, R. | |
| A randomized trial of 5-fluorouracil alone vs 5-FU and high dose leucovorin in untreated advanced colorectal cancer patients | 1-gen-1988 | Nobile, Mt; Canobbio, L; Sobrero, Alberto; Galligioni, E; Vidili, Mg; Rubagotti, A; Sertoli, Mr; Rosso, R. | |
| Activity of 4'Epi-doxorubicin on normal haemopoietic precursor cells in mice | 1-gen-1982 | Sobrero, Alberto; Muzzulini, C; D'Amore, F; Ghio, R; Pannacciulli, I. | |
| Activity of continuous infusion 5-Fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-Fluorouracil | 1-gen-1993 | A., Mori; S., Bertoglio; A., Guglielmi; C., Aschele; E., Bolli; L., Tixi; R., Rosso; Sobrero, Alberto | |
| Adjuvant chemotherapy in the treatment of colon cancer: randomized multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC) | 1-gen-2003 | Di Costanzo, F; Sobrero, Alberto; Gasperoni, S; Dogliotti, L; Frassineti, L; Falcone, A; Lionetto, R; Bruzzi, P; Luppi, G; Gallo, L; Conte, P; Comandone, A; Turci, D; Marzola, M; Folco, U; Pfanner, E; Mestriner, M; Boni, C; Galli, C; Tonato, M; Rosso, R. | |
| Adjuvant sequential methotrexate --> 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer | 1-gen-2005 | Sobrero, Alberto; Frassineti, G; Falcone, A; Dogliotti, L; Rosso, R; Costanzo, Fd; Bruzzi, P; Intacc, | |
| Adjuvant therapy for colon cancer: 12 months, 9 months, 6 months ... why not 3 months? | 1-gen-2005 | Sobrero, Alberto; Sciallero, S. | |
| Adjuvant treatment of colorectal cancer in the elderly | 1-gen-1995 | C., Aschele; A., Guglielmi; L., Tixi; E., Bolli; A., Mori; R., Lionetto; R., Rosso; Sobrero, Alberto | |
| Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial | 1-gen-2007 | Cascinu, S; Labianca, R; Barone, C; Santoro, A; Carnaghi, C; Cassano, A; Beretta, Gd; Catalano, V; Bertetto, O; Barni, S; Frontini, L; Aitini, E; Rota, S; Torri, V; Floriani, I; Italian Group for the Study of Digestive Tract, Cancer; Pozzo, C; Rimassa, L; Mosconi, S; Giordani, P; Ardizzoia, A; Foa, P; Rabbi, C; Chiara, S; Gasparini, G; Nardi, M; Mansutti, M; Arnoldi, E; Piazza, E; Cortesi, E; Pucci, F; Silva, Rr; Sobrero, Alberto; Ravaioli, A. | |
| Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients | 1-gen-1996 | A., Guglielmi; C., Aschele; F., Grossi; L., Tixi; Sobrero, Alberto | |
| Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy | 1-gen-2009 | Peeters, M; Siena, S; Van Cutsem, E; Sobrero, Alberto; Hendlisz, A; Cascinu, S; Kalofonos, H; Devercelli, G; Wolf, M; Amado, Rg | |
| Bevacizumab plus fluorouracil: the value of being part of a developing story | 1-gen-2005 | Sobrero, Alberto; Bruzzi, P. | |
| Biochemical determinants of antineoplastic activity of fluoropyrimidines | 1-gen-1989 | Sobrero, Alberto; Russello, O; Aschele, C; Gamba, E; Bruzzo, C; Maioli, D; Nobile, Mt; Vidili, Mg; Nicolin, A. | |
| Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer : economic evaluation in an Italian NHS setting | 1-gen-2008 | Di Costanzo, F; Ravasio, R; Sobrero, Alberto; Bertetto, O; Vinante, O; Luppi, G; Labianca, R; Amadori, D; Barone, C; Carlo Merlano, M; Longo, F; Mansueto, G; Antonuzzo, L; Gasperoni, S. | |
| Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study | 1-gen-2005 | Twelves, Cj; Butts, Ca; Cassidy, J; Conroy, T; Braud, F; Diaz Rubio, E; Tabernero, Jm; Schoffski, P; Figer, A; Brunet, R; Grossmann, J; Sobrero, Alberto; Van Cutsem, Ej | |
| Chemosensitivity of human tumor clonogenic cells simultaneously assayed in agar diffusion chambers and in a two-layer agar culture system | 1-gen-1984 | Sobrero, Alberto; Marsh, Jc | |
| Chemotherapy: which drug and when? | 1-gen-2010 | Sobrero, Alberto; Bennicelli, E. | |
| Clinical aspects of drug resistance | 1-gen-1986 | Sobrero, Alberto; Bertino, Jr | |
| Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel Liver Metastases Workshop | 1-gen-2009 | Nordlinger, B; Van Cutsem, E; Gruenberger, T; Glimelius, B; Poston, G; Rougier, P; Sobrero, Alberto; Ychou, M; European Colorectal Metastases Treatment, Group; Sixth International, Colorectal |